AACR 2023 Conference Coverage
T

First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor of YAP/TEAD, in Pts With Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors With NF2 Mutations

By AACR 2023 Conference Coverage FEATURING Timothy Yap
By AACR 2023 Conference Coverage FEATURING Timothy Yap
49 views
May 4, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
15:02
Michelle Shiller

Value of NGS in Solid Tumors

36:31
Oluf Dimitri Røe

Emerging Biomarkers for Mesothelioma: Prognostic/Predictive Biomarke…

20:33
Fereidoun Abtin

Discussion on Malignant Pleural Mesothelioma: Outcomes and Effects o…

29:05
Kevin Lamote

An Exhaled Breath Biopsy Earmarks Exclusive Screening for Malignant …

18:10
Raja Flores

The Role of Decortication in Mesothelioma

18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
35:40
Balazs Halmos

Year in Review: Lung Cancer

11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

26:38
University of Colorado Department of Medicine

Key to Successful Lung Cancer Screening and Lung Nodule Program

Feat. N. Thomas
27:04
Fengting Yan

Cancer Screening Molecular Tools

25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
25:18
Janakiraman Subramanian

Updates in Small Cell Lung Carcinoma

07:05
UNC Lineberger Comprehensive Cancer Center

Lung Cancer Screening in Primary Care

Feat. N. Robertson
18:35
2023 Evolution Conference

Recent Updates in SCLC

Feat. S. Kazmi
07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
30:27
Insights from 2023 ESMO Annual Meeting

Perioperative Immunotherapy Strategies in Resectable NSCLC After ESM…

Feat. G. Mountzios